Large UK study shows low rates of HIV testing, even among those who think they are at risk of HIV
Evidence for PrEP efficacy grows, but implementation presents challenges
Tenofovir alafenamide fumarate at what price? No more than $1000 a year above existing tenofovir formulation, says model
Two-drug ART with dolutegravir-lamivudine would be cost-effective and achieve substantial cash savings
US syringe funding ban impedes HIV and hepatitis C prevention
UK maintains the largest HIV epidemic in western Europe
Sofosbuvir/daclatasvir combination could be produced for $200 per hepatitis C cure
Drug resistance acquired during HIV PrEP rapidly disappears after medication is discontinued
Grazoprevir/elbasvir cures more than 90% of people with HIV/HCV co-infection